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Iron	overload	is	the	hallmark	of	hereditary	hemochromatosis	and	a	complication	of	iron-loading	anemias	
such	as	β-thalassemia.	Treatment	can	be	burdensome	and	have	significant	side	effects,	and	new	therapeu-
tic	options	are	needed.	Iron	overload	in	hereditary	hemochromatosis	and	β-thalassemia	intermedia	is	
caused	by	hepcidin	deficiency.	Although	transgenic	hepcidin	replacement	in	mouse	models	of	these	dis-
eases	prevents	iron	overload	or	decreases	its	potential	toxicity,	natural	hepcidin	is	prohibitively	expensive	
for	human	application	and	has	unfavorable	pharmacologic	properties.	Here,	we	report	the	rational	design	
of	hepcidin	agonists	based	on	the	mutagenesis	of	hepcidin	and	the	hepcidin-binding	region	of	ferroportin	
and	computer	modeling	of	their	docking.	We	identified	specific	hydrophobic/aromatic	residues	required	
for	hepcidin-ferroportin	binding	and	obtained	evidence	in	vitro	that	a	thiol-disulfide	interaction	between	
ferroportin	C326	and	the	hepcidin	disulfide	cage	may	stabilize	binding.	Guided	by	this	model,	we	showed	
that	7–9	N-terminal	amino	acids	of	hepcidin,	including	a	single	thiol	cysteine,	comprised	the	minimal	
structure	that	retained	hepcidin	activity,	as	shown	by	the	induction	of	ferroportin	degradation	in	reporter	
cells.	Further	modifications	to	increase	resistance	to	proteolysis	and	oral	bioavailability	yielded	minihep-
cidins	that,	after	parenteral	or	oral	administration	to	mice,	lowered	serum	iron	levels	comparably	to	those	
after	parenteral	native	hepcidin.	Moreover,	liver	iron	concentrations	were	lower	in	mice	chronically	treated	
with	minihepcidins	than	those	in	mice	treated	with	solvent	alone.	Minihepcidins	may	be	useful	for	the	
treatment	of	iron	overload	disorders.
Introduction
Hepcidin is a peptide hormone that mediates systemic iron 
homeostasis in vertebrates (1). Hepcidin controls plasma 
iron concentrations by inhibiting dietary iron absorption and 
release of recycled iron from macrophages. The hormone acts 
by inducing the endocytosis of its receptor ferroportin, the sole 
known cellular exporter of iron. Hepcidin deficiency causes 
or contributes to iron overload in several diseases, including 
hereditary hemochromatosis (2, 3), β-thalassemia (4, 5), and 
chronic hepatitis C (6, 7).
Current treatment modalities for iron overload include phle-
botomy and iron chelation. Phlebotomy is a relatively inexpen-
sive and effective treatment for hereditary hemochromatosis but 
is not satisfactory for all patients. Some patients do not tolerate 
phlebotomy because of concurrent anemia, poor vascular access, 
adverse physiological responses to phlebotomy, fears, religious 
beliefs, and the lack of long-term convenient access to phlebot-
omy centers (8). Even the patients who are compliant with phle-
botomy treatment may prefer oral therapy if it were available.
In β-thalassemia, phlebotomy is generally not feasible because it 
worsens anemia, and iron overload is treated by regular chelation 
(9). Iron chelators have side effects ranging from mild to very seri-
ous, and compliance is often suboptimal. Iron overload remains a 
major cause of morbidity and mortality in β-thalassemia.
Additional therapeutic options are clearly desirable. Given the 
causal role of hepcidin deficiency in the development of iron 
overload, replacement of hepcidin would be a rational approach 
to the prevention and treatment of iron overload in these dis-
orders (10). However, the use of natural hepcidin as a potential 
replacement therapy in hepcidin-deficient conditions has major 
limitations. Bioactive hepcidin is 25–amino acids long and has 
4 disulfide bonds, rendering the production of a correctly folded 
full-length hepcidin expensive. The half-life of natural hepcidin 
is very short (11) due to its rapid renal excretion. Furthermore, 
peroral absorption of hepcidin would be low due to its large size 
(~2.7 kDa). In search of alternatives to full-length hepcidin, we 
carried out a structure-function analysis of the hepcidin-fer-
roportin interface. Based on this information, we developed 
a series of 7– to 9–amino acid peptides, “minihepcidins,” that 
mimic the activity of hepcidin in cell-based bioassays and in 
mice. Our findings establish the feasibility of small, drug-like 
hepcidin agonists for the treatment of iron overload disorders 
due to hepcidin deficiency.
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Results
Definition of the extracellular loop of ferroportin  
involved in hepcidin binding
We previously showed that an extracellular ferroportin residue, 
C326, is essential for hepcidin binding (12), but the extent of the 
extracellular loop surrounding C326 was not known. In the 2 pub-
lished models of ferroportin topology, the extracellular loop con-
taining C326 spans the region from D325 to S342 (13) or F316 to 
T334 (14). We subjected the proposed ends of the extracellular loop 
to cysteine-scanning mutagenesis. In WT ferroportin, C326 and pos-
sibly C205 have extracellular location (13). Because of that, a double 
mutant (C205S/C326S) of human ferroportin-GFP was used as a 
template for site-directed mutagenesis to introduce cysteines in 
multiple positions between M312 and L345. To determine which 
of the newly introduced cysteines were located on the cell surface, 
HEK293T cells were transfected with plasmids encoding control 
or mutant ferroportin-GFP and biotinylated using nonpermeable, 
sulfhydryl (SH)-reactive biotin-maleimide. Streptavidin-peroxidase 
probing of SDS-PAGE blots of immunoprecipitated ferroportin-
GFP showed that, as expected, WT ferroportin-GFP but not the 
C205S/C326S double mutant was biotinylated (Figure 1A). Ferro-
portin mutants with cysteine substitutions in the region between 
M312 and L322 and between I344-L345 were expressed on the plas-
ma membrane (Figure 1B) but were not biotinylated, suggesting 
that these residues are located in a transmembrane (or intracellular) 
region. In contrast, G323, F324, T334C, S338C, S340C, and S343C 
mutant ferroportins were all biotinylated, demonstrating their 
extracellular location and indicating that the extracellular loop con-
taining C326 likely extends from G323 to S343.
A previous study (15) described the F324-S343 ferroportin region 
as the hepcidin-binding domain (HBD) and reported that a syn-
thetic peptide corresponding to the HBD interacts with hepcidin 
in a manner similar to that of the membrane-associated cellular 
ferroportin. However, in our studies, the synthetic HBD peptide 
(RR-FDCITTGYAYTQGLSGSILS-RR) did not bind hepcidin 
specifically. As analyzed by surface plasmon resonance, synthetic 
human hepcidin interacted equally with the WT and C326S HBD 
peptide (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI57693DS1) or with unal-
kylated and alkylated HBD (data not shown). In contrast, similar 
modifications to ferroportin have dramatic effects on hepcidin 
binding (12). Any interactions that were observed between human 
hepcidin and HBD were nonspecific and probably due to hepcidin 
aggregating readily on a variety of surfaces (Supplemental Figure 
1B). The reverse configuration, in which hepcidin was coated on 
the chip and HBD was in fluid phase, did not result in any binding 
(Supplemental Figure 1C). The results indicate that the synthetic 
F324-S343 peptide does not bind hepcidin specifically and that 
the segment does not function as an autonomous HBD.
Ferroportin residues in the vicinity of C326 also participate  
in hepcidin binding
To determine whether ferroportin residues other than C326 con-
tribute to hepcidin binding, we mutagenized to alanine each resi-
due in the C326 extracellular loop of WT human ferroportin (Fpn)-
GFP except for A332, which was substituted with D (aspartate). 
HEK293T cells were transfected with the ferroportin mutants, and 
the uptake of radiolabeled hepcidin was measured. To account for 
the variability of transfection efficiency, radioactive counts were 
normalized to the expression of ferroportin-GFP as determined 
by Western blotting. D325A protein was expressed at very low 
levels, and we therefore tested the mutant D325N, which had a 
normal level of expression. Remarkably, substitutions in the first 
half of the extracellular loop markedly reduced hepcidin binding, 
whereas mutations in the second half did not interfere with hepci-
din binding (Figure 1C). However, a reduction in hepcidin binding 
by a specific mutation may occur not only because the residue is 
involved in contacting hepcidin but because of mistrafficking of 
the mutant protein or because of a conformational change, lead-
ing to reduced accessibility of the binding site containing C326. To 
address these possibilities, we used SH-reactive biotin-maleimide 
to biotinylate cells transfected with the ferroportin-GFP mutants 
from Figure 1C. The mutations that reduced hepcidin binding 
without affecting the accessibility of C326 were F324A and Y333A 
but not D325N, I327A, and A332D (Figure 1D). Thus, F324 and 
Y333 likely make direct contact with hepcidin. The fluorescence 
microscopy images of the mutants’ cellular localization are shown 
in Supplemental Figure 2.
Identification of hepcidin residues critical for binding to ferroportin
We showed previously that deletion of the 5 N-terminal resi-
dues of hepcidin ablated the ability of the peptide to cause fer-
roportin degradation (16). By substituting individual N-terminal 
residues (residues 1–6 and 8), we also showed that H3, F4, and I6 
were important for the peptide activity and that those positions 
required hydrophobic side chains for interaction with ferropor-
tin (17). Here, we mutagenized the next large hydrophobic resi-
due, F9. Substitutions of F9 with alanine or cyclohexylalanine (a 
nonaromatic hydrophobic residue) resulted in 100- and 10-fold 
reduced activity respectively, suggesting that position 9 requires 
an aromatic side chain (Figure 2A).
Because our previous study on the ferroportin thiol residue C326-
SH (12) indicated that disulfide bond formation may occur during 
hepcidin-ferroportin interaction, we next focused on the effect of 
individual disulfide bond substitutions on hepcidin peptide activ-
ity. Although we previously partially explored this question (16), 
the hepcidin structure has since been revised (18), and we generated 
synthetic hepcidin mutants in which we substituted pairs of cyste-
ines with alanines according to the revised connectivity (C7A/C23A, 
C10A/C13A, C11A/C19A, C14A/C22A). A dose-response analysis 
of the mutant peptide activity (Figure 2B) showed that all these 
mutants had a similar decrease in activity (up to 100 fold). Circular 
dichroism spectroscopy indicated that the mutant peptides had 
slightly more disordered structure than the native peptide (Supple-
mental Figure 3), perhaps partially accounting for the diminished 
activity. Given that none of the mutants displayed a complete loss 
of activity, the result suggests that if disulfide exchange is involved 
in hepcidin binding, more than one disulfide bond could partici-
pate in exchange with C326-SH on ferroportin.
RosettaDock computer modeling
To gain further insight into the hepcidin-ferroportin interaction, we 
performed computer modeling. The input structures were the full-
length hepcidin (PDB 2KEF), with the most recent disulfide bond 
assignment (18), and a region of ferroportin (residues 306–362) 
encompassing the C326 extracellular loop and flanking transmem-
brane helices, with structure based on a recently developed theo-
retical model of ferroportin molecule (19). Ferroportin and hepci-
din structures were refined using HyperChem 7.5 and GROMACS 
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before docking studies. The initial stage docking program ZDOCK 
(20) was first used to identify the lowest energy conformer set, and 
this ensemble was optimized using the RosettaDock program 
(21). The RosettaDock refinement run generated 1,000 structures 
whose energy scores were plotted versus the root mean square 
distance from the starting input conformation (Figure 3A). The 
plot showed the optimal energetic “funnel” of low-energy struc-
tures. The 10 best-scoring low-energy structures all had the 
N terminus of hepcidin as the part forming the interface with fer-
roportin. Of those 10 structures, the conformation most compat-
Figure 1
Defining the hepcidin-binding loop on ferroportin. 
(A) To detect the boundaries of the C326-containing 
extracellular loop, certain residues between M312 
and L345 on the human Fpn-GFP C205S/C326S 
mutant were substituted with cysteine. Mutant con-
structs were transfected into HEK293T cells, and 
cell-surface biotinylation was performed using a 
nonpermeable, SH-reactive biotin-maleimide. Pro-
tein lysates were immunoprecipitated with anti-GFP 
antibody, analyzed by SDS-PAGE, blotted, and 
probed with streptavidin-peroxidase to determine 
which mutated residues had extracellular localiza-
tion. The bottom row indicates the amount of Fpn-
GFP that was immunoprecipitated. Each mutant 
was tested in at least 3 separate experiments. (B) 
Confocal microscopy of HEK293 cells transfected 
with cysteine substitution mutants. Mutant proteins 
M312C, L314C, F316C, Y318C, L322C, I344, and 
L345 were all displayed on the cell surface similar 
to WT ferroportin-GFP, indicating that mistraffick-
ing was not the reason for the absence of cell-sur-
face biotinylation in A. Original magnification, ×63. 
(C) To define the contribution of residues in the 
C326 extracellular loop to hepcidin binding, ala-
nine-scanning mutagenesis and other substitutions 
were performed as indicated. After transfection of 
HEK293T cells, cellular uptake of 125I-hepcidin was 
determined and normalized to the Fpn-GFP levels 
in each sample, determined by Western blotting. 
Each bar represents the average of 3 to 4 separate 
experiments, and error bars indicate standard devi-
ation. (D) Cell-surface biotinylation of constructs 
from C. Of the mutants that showed decreased 
hepcidin uptake, only F324A and Y333A mutants 
had thiol-specific biotinylation similar to that of WT 
Fpn-GFP, whereas others (D325N, I327A, A332D) 
had decreased cell-surface thiol-biotinylation, sug-
gesting that these mutants may be mistrafficked or 
that a conformational change may be blocking the 
C326-SH accessibility.
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ible with our mutagenesis data (second-lowest energy structure) 
was used as the final hypothetical model of the ferroportin-hepci-
din complex (Figure 3B and Supplemental Figure 4).
The model highlighted that aromatic and hydrophobic side 
chain interactions can drive the hepcidin-ferroportin interaction 
(Supplemental Table 1). In the model, H3, F4, and I6 of hepcidin 
formed a hydrophobic pocket for the interaction with Y333 of fer-
roportin, and F9 of hepcidin interacted with F324 of ferroportin 
through pi-stacking, in agreement with our mutagenesis data. The 
model also positioned the C326 residue in close proximity to the 
hepcidin disulfide framework.
Minihepcidins display agonist activity
The mutagenesis approach as well as RosettaDock modeling sug-
gested that hepcidin residues important for binding to ferroportin 
are located at the highly conserved N terminus of the peptide and 
prominently include residues H3, F4, I6, and F9. We thus synthe-
sized short peptides (minihepcidins), consisting of up to 9 N-ter-
minal amino acids of hepcidin (Supplemental Table 2), and tested 
their ability to cause ferroportin-GFP degradation in the cellular 
bioassay. These first generation minihepcidins showed substantial 
agonist activity (Figure 4), although they were less potent than the 
full-length hepcidin (EC50 = 9 nM). The minihepcidin containing 
9 N-terminal residues (hep9, DTHFPICIF; EC50 = 76 nM; Supple-
mental Figure 5) was more active than shorter minihepcidins.
Thiol cysteine is required for minihepcidin activity
Because our previous study showed that a thiol form of the C326 
residue on ferroportin was necessary for hepcidin binding and 
that the mutant with isosteric substitution C326S did not bind 
hepcidin in vitro (12) and caused hepcidin resistance in vivo (22), 
we hypothesized that a disulfide exchange between C326 and the 
disulfide framework of hepcidin may occur upon hepcidin bind-
ing to ferroportin. To determine whether disulfide bonding could 
also be involved in minihepcidin binding to ferroportin, we tested 
the requirement for cysteine on minihepcidin by mutating the C7 
residue of hep9. We found that the activity of hep9 depended on 
its ability to participate in disulfide exchange. Isosteric substitu-
tion with serine (C7S) or blocking of C7 thiol with a t-butyl group 
(C7-S-t-but), which prevents disulfide exchange, ablated the ago-
nist activity of hep9 (Figure 5A). However, the activity was consid-
erably preserved when the blocking group was disulfide linked to 
C7 (C7-SS-t-but) and was therefore capable of disulfide exchange.
These results strongly suggest that the minihepcidin-ferro-
portin interaction is dependent on the thiol-thiol interaction or 
Figure 2
Hepcidin amino acid residues important for binding to ferro-
portin. Full-length 25–amino acid hepcidin variants were pre-
pared by chemical synthesis and oxidatively refolded. The 
peptide activity was measured by a flow cytometry–based 
assay detecting ferroportin-GFP degradation. (A) F9 substi-
tution with nonaromatic cyclohexylalanine (cha) or alanine 
caused a 10- and 100-fold decrease in peptide activity. (B) 
Pairwise substitutions of cysteines with alanines to remove 
individual disulfide bonds reduced bioactivity to a similar 
extent. Each data point is the average of 3 to 4 individual 
experiments and error bars indicate SD.
Figure 3
A RosettaDock model of the interaction between hepcidin and the fer-
roportin loop surrounding C326. (A) Plot of the full set of 1,000 struc-
tures generated in the RosettaDock refinement run. The energy score 
versus the root mean square (rms) distance from the starting structure 
shows the optimal energetic funnel of low-energy structures clustered 
around a single position. The plot indicates that the docking algorithm 
has reached a good local minimum and that the lowest scoring (low-
est free energy) structures are the most stable. The second-lowest 
energy structure was most compatible with our mutagenesis data and 
is presented in B. (B) Hepcidin sequence is shown in pink, with yellow 
disulfide connectivities. Ferroportin extracellular loop is shown in cyan, 
transmembrane helices are shown in gray, and the sulfur of C326 is 
shown in yellow. The strongly interacting side chain pairs are displayed 
in thicker lines. Hydrogens are not shown. The model identified hydro-
phobic interactions between H3, F4, and I6 on hepcidin and Y333 on 
ferroportin and pi-stacking interaction between F9 and F324. The inter-
action of aromatic residues on the hepcidin and ferroportin surfaces 
brings C326 close to the disulfide network of hepcidin (disulfide cage), 
raising the possibility of transient disulfide exchange.
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disulfide formation and that the hepcidin-ferroportin interac-
tion could involve disulfide exchange. To further examine this, 
we tested whether the hepcidin-ferroportin complex is affected 
by reducing agents. In our previous experiments, we noted that 
125I-hepcidin forms a complex with ferroportin that does not 
dissociate during protein extraction, immunoprecipitation, and 
SDS-PAGE. However, this complex readily dissociated in the pres-
ence of DTT (Figure 5B), supporting the possibility of hepcidin-
ferroportin disulfide exchange.
Design and in vitro bioassay of minihepcidins
In order to optimize the agonist activity, we designed additional 
minihepcidins of varying lengths and structural modifications 
(Supplemental Table 2). All peptides were synthesized as carboxy-
amides (-CONH2) to make their C terminus similar to the corre-
sponding intact hepcidin segment. The peptide activity was tested 
in a cellular bioassay in vitro, measuring their ability to cause deg-
radation of ferroportin-GFP (16).
Substitution or stabilization of the C7 thiol group in hep9 
decreases bioactivity. To increase the stability of minihep-
cidins, we synthesized circular peptides by introducing 
an internal disulfide bond with C7. We also modified 
the size and reactivity of the amino acid correspond-
ing to C7 by introducing various cysteine analogs at 
that position. All of these cysteine analogs showed 
decreased bioactivity relative to that of hep9.
Retro-inverso minihepcidins are bioactive. To increase the 
resistance of minihepcidins to proteolysis in vivo, we 
introduced unnatural amino acids (chemical structures 
shown in Supplemental Table 3) or synthesized retro-
inverso analogs. Retro-inverso peptides are composed of 
D-amino acids assembled in the reverse order from that 
of the parent L-peptide sequence, making them steri-
cally similar to the original but much more resistant to 
proteolysis. Retro-inverso hep9 analog (ri-hep9, FICIP-
FHTD) and retro-inverso hep3-9 (ri-hep3-9, FICIPFH) 
caused ferroportin degradation in vitro, although with 
several fold lower activity than that of hep9.
Effects of other peptide modifications. Additional peptide 
variants were pegylated in order to increase solubility, 
reduce immunogenicity, and increase circulatory time 
by reducing renal clearance. To increase the intestinal 
uptake of minihepcidins via enterohepatic circulation 
of bile acids, the pegylated retro-inverso hep9 was con-
jugated with chenodeoxycholic or ursodeoxycholic bile 
acids (cheno-ri-hep9 and urso-ri-hep9). Cheno-ri-hep9 
had similar activity in vitro to that of unmodified hep9, while urso-
ri-hep9 had 10-fold lower activity. We also synthesized retro-inver-
so hep9 conjugated to palmitoyl groups because palmitoylation 
of peptides could increase intestinal absorption, reduce renal 
excretion through increased binding to albumin, and potentially 
increase affinity for cell membranes (23). Singly palmitoylated 
retro-inverso hep9 (palmitoyl-ri-hep9) was as active as hep9, but 
the peptide with 2 palmitoyl groups had no activity. Beta-propel-
ler and collagen domain modifications, designed to multimerize 
minihepcidins and thereby reduce their renal excretion, resulted 
in inactive minihepcidins.
Minihepcidins induce hypoferremia in mice
Several of the peptides that were most active in vitro were selected 
for testing in mice. Although our minihepcidins were derived from 
the human sequence, the human hepcidin is active in the mouse 
presumably because of the high degree of identity between mouse 
and human sequences of hepcidin and ferroportin. Selected ana-
Figure 4
Minihepcidins are effective hepcidin agonists. The activ-
ity of synthetic minihepcidins was determined by flow 
cytometric quantitation of ferroportin-GFP degradation in 
stably transfected HEK293 cells. Each point is an aver-
age of 5 to 6 experiments and error bars indicate SD. 
hep8, DTHFPICI; hep7, DTHFPIC; hep3-9, HFPICIF; 
hep3-8, HFPICI; Hep3-7, HFPIC; Hep4-7, FPIC.
Figure 5
Evidence for the role of disulfide exchange in the hepcidin-ferroportin interaction. 
(A) The agonist activity of minihepcidin depends on its thiol reactivity. Hep9 was 
modified at residue C7; C7-SS-tbut contains an exchangeable tert-butyl group 
disulfide-linked to C7; C7-S-tbut contains a tert-butyl group in a thioether linkage 
to C7, which prevents disulfide exchange; and C7S contains a serine in posi-
tion 7 instead of a cysteine. Each data point is the average of 3 to 4 individual 
experiments and error bars indicate SD. (B) Reducing agents disrupt 125I-hepcidin 
association with Fpn-GFP. 125I-hepcidin (125I-hep) was added to cells expressing 
ferroportin-GFP for 15 minutes, and total cellular protein was immunoprecipitated 
using anti-GFP antibody. The sample was split into 2 identical aliquots, and DTT 
was added to 1 of the aliquots (final concentration 100 mM). The amount of 
immunoprecipitated Fpn-GFP was determined by Western blotting. Similar experi-
ments were performed at least 5 times.
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logs were injected intraperitoneally into mice, and a decrease in 
serum iron was measured 4 hours after injection. Control mice 
were treated with the diluent or with 20 nmoles human hep25 
(~50 μg per mouse). Even at 10-times higher concentrations, 
minihepcidin hep9 had no effect on serum iron levels, presumably 
because it was rapidly degraded, but a more stable retro-inverso 
hep9 showed significant activity (P = 0.028; Figure 6A). Mini-
hepcidins conjugated to fatty or bile acids were even more active. 
Injection of 20 nmoles palmitoyl-ri-hep9 caused almost as large 
a decrease in serum iron levels as the equivalent dose of hep25 
(Figure 6B). Importantly, when the cysteine residue in palmitoyl-
ri-hep9 was substituted with serine, no serum iron decrease was 
observed (Supplemental Figure 6). Injection of a higher dose of 
palmitoyl-ri-hep9 (200 nmoles) caused more profound hypofer-
remia than did injection of hep25, with an 80% drop in serum iron 
(Figure 6B). Even a 7–amino acid retro-inverso peptide (ri-hep3-9; 
Figure 6B) was bioactive after parenteral injection, causing a 70% 
decrease in serum iron at 200 nmoles. The decrease in serum iron 
was not a consequence of the induction of endogenous hepcidin, 
as murine hepatic hepcidin-1 mRNA levels measured by qRT-PCR 
were not increased in agonist-treated mice compared with those in 
controls (Supplemental Figure 7).
Selected minihepcidins are bioactive when administered by gavage
In many situations, the most desirable method of drug delivery 
is by the peroral route. To test whether minihepcidins adminis-
tered orally would exert a hypoferremic effect, we gavaged mice 
with 200 nmoles retro-inverso hep9 that was palmitoylated or 
conjugated to bile acids (chenodeoxycholic or ursodeoxycholic 
acid). All 3 minihepcidins caused a significant decrease in serum 
iron compared with that in controls gavaged with diluent or 
with Hep25 (Figure 6C).
Minihepcidins prevent liver iron overload in hepcidin-1  
knockout mice
In a proof-of-principle experiment, we examined the chronic 
effect of minihepcidin injections on liver iron accumulation in a 
mouse model of hereditary hemochromatosis. We chose hepci-
din-1 knockout mice to eliminate any possibility of endogenous 
hepcidin contributing to the regulation of iron loading. Hepc1–/– 
animals were injected parenterally with palmitoyl-ri-hep9 (100 
nmoles; n = 7) or diluent (n = 6) daily for 2 weeks. The end point 
hemoglobin (15 ± 2 g/dl and 15.9 ± 1.5 g/dl in palmitoyl-ri-hep9 
and control group, respectively) and other hematological param-
eters were similar between the 2 groups of mice, indicating that 
minihepcidin injections did not cause iron-restricted erythropoi-
esis. However, the nonheme iron concentration of the liver was sig-
nificantly lower in animals treated with the minihepcidin (13.7 ± 4 
μmoles/g wet weight) than that in those treated with diluent only 
(27.1 ± 13.7 μmoles/g wet weight) (P = 0.03; Figure 6D).
Discussion
In hereditary hemochromatosis, hepcidin deficiency is a conse-
quence of destructive mutations in the genes encoding hepcidin 
(24) or one of its regulators, HFE (3) (most common), transferrin 
receptor 2 (25), or hemojuvelin (26). Hepcidin deficiency results 
Figure 6
Bioactivity of parenteral and oral minihep-
cidins in mice. (A) Full-length hepcidin 
(20 nmoles), minihepcidins (200 nmoles), 
or diluent were injected intraperitoneally 
(n = 6 animals per treatment), mice were 
euthanized after 4 hours, and nonheme iron 
levels were determined in serum. ri-hep9, 
retro-inverso hep9; Cyc-1, minihepcidin with 
a disulfide bond (CDTHFPICIF). *P = 0.003 
and **P = 0.035 in comparison with control 
mice. (B) Full-length hepcidin (20 nmoles), 
minihepcidins (20 and 200 nmoles), or dilu-
ent were injected intraperitoneally into mice 
(n = 5–7 per treatment), and their serum 
iron was measured after 4 hours. ri-hep3-9, 
retro-inverso HFPICIF. *P = 0.02; **P = 0.002; 
†P = 0.015; #P < 0.001. (C) Peptides (200 
nmoles) or diluent were administered orally 
by gavage, and serum iron measured was 
after 4 hours. The results are expressed as 
the percentage of decrease in serum iron 
as compared with the serum iron levels in 
PBS-treated mice to normalize for the varia-
tions in absolute serum iron levels between 
experiments. *P = 0.006; **P = 0.003; 
***P = 0.01. (D) Hepcidin-1 knockout mice 
were injected intraperitoneally with palm-
ri-hep9 (100 nmoles per mouse; n = 7) or 
diluent (n = 6) daily for 2 weeks. Liver iron 
content was measured on day 15. *P = 0.03. 
Error bars represent SD.
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in excessive intestinal iron absorption and maldistribution of 
tissue iron. If severe and untreated, the disease can progress to 
cirrhosis, hepatocellular carcinoma, and endocrine and cardiac 
problems. In the US, about 0.4% of people of mixed European 
descent have hereditary hemochromatosis mutations that put 
them at risk for iron overload (27).
Iron overload also occurs in β-thalassemia, a disease that affects 
millions of patients whose origins are in the Mediterranean basin 
and Asia, regions historically affected by endemic malaria (28). In 
β-thalassemia, hepcidin is suppressed by increased erythropoietic 
activity through mechanisms that are still incompletely defined. In 
the absence of transfusions (β-thalassemia intermedia), hepcidin 
levels are very low (4, 5), and patients develop iron overload similar 
to that of severe hereditary hemochromatosis and may succumb 
to iron overload if untreated (29). In β-thalassemia major, trans-
fusions rather than dietary iron absorption are the predominant 
cause of iron overload. Here, hepcidin levels are higher, because 
ineffective erythropoiesis is suppressed by transfusions and also 
because the additional iron load stimulates hepcidin production. 
However, in the intervals between transfusions, hepcidin concen-
trations progressively decrease toward the end of the interval (4, 5, 
30), and this recurrent lowering of hepcidin may also contribute 
to iron overload in β-thalassemia major.
Milder hepcidin insufficiency is seen in chronic liver disease, 
including viral hepatitis (6, 7, 31). The cause of hepcidin suppres-
sion in these diseases is not yet clear, but the resulting chronic iron 
loading in the liver worsens the prognosis (32).
Therapeutic augmentation of hepcidin levels would be expected 
to curb hyperabsorption of dietary iron in these patients. The proof 
of this concept was achieved in mouse model of HFE hereditary 
hemochromatosis, in which the introduction of a hepcidin trans-
gene into Hfe–/– mice prevented the development of iron overload 
(33). Hepcidin also causes redistribution of iron when iron over-
load is already established. Hepcidin induction in HFE-null mice 
carrying a Tet-inducible hepcidin construct did not acutely reverse 
the iron overload but did shift the excess iron from hepatocytes 
and other parenchymal cells to macrophages (34). Macrophages 
are relatively resistant to the toxic effects of iron (35), as demon-
strated by the relatively benign course of “ferroportin disease,” in 
which iron accumulates in macrophages. Most affected patients 
have no clinical manifestations, despite often severe iron overload 
(36). Thus, hepcidin-mediated redistribution of iron from paren-
chyma to macrophages in iron-overloaded patients could poten-
tially limit iron toxicity in the heart, the pancreas, and the liver.
In addition to the beneficial effect of hepcidin on iron balance 
and distribution, recent studies suggest that hepcidin may also 
improve disordered erythropoiesis in β-thalassemia. Although 
the mechanism is still not understood, transgenic expression of 
hepcidin in a mouse model of β-thalassemia intermedia increased 
hemoglobin and decreased extramedullary erythropoiesis (37).
Using full-length hepcidin for the treatment of iron overload con-
ditions would be expected to be expensive, not only because the syn-
thesis and refolding of hepcidin with 4 disulfide bonds allows for a 
large number of alternative folds but also because of the relatively 
high dose required for its biological effect. Even assuming that 
hepcidin could be produced at a cost comparable to that of recom-
binant insulin, a typical dose of hepcidin would likely be many 
fold higher than that of insulin. In human patients with type 1 
diabetes mellitus (and mouse models), a typical dose of insulin is 
0.2–0.7 U/kg/d or 9–32 μg/kg/d (1 U is the biological equivalent 
of 45.5 μg pure crystalline insulin). A typical dose of hepcidin, on 
the other hand, is 50 μg/mouse/d or 2 mg/kg/d, which is nearly 
100-times higher than the typical dose of insulin. Given the current 
limitations of peptide synthetic technology, designing more potent 
and less expensive hepcidin analogs would be advantageous.
In this study, we developed small peptides, minihepcidins, that 
act as hepcidin agonists. Their rational design was facilitated by 
the identification of the region on hepcidin and ferroportin mol-
ecules that is critical for their binding. Together with our previous 
structure-function studies (16, 17), we showed that hydrophobic 
contacts dominate the ligand-receptor interaction and that several 
N-terminal amino acids of hepcidin, up to residue 9, are critical for 
its activity. We therefore used the first 9 residues as the scaffold for 
minihepcidin design. We also found that the ability to participate 
in thiol-thiol interactions is essential for minihepcidin activity. 
Blocking the only cysteine (C7) with a protective group abrogated 
the peptide activity unless the protective group was added in such 
a way that disulfide exchange was possible. Furthermore, in con-
trast to its Cys-containing counterpart, minihepcidin bearing the 
Cys to Ser substitution did not cause serum iron decrease in mice 
after intraperitoneal injection.
To improve agonist activity, we developed the minihepcidins 
with structural modifications that addressed some undesirable 
physicochemical properties of the minihepcidin scaffold, such as 
thiol instability, hydrophobicity, poor gastrointestinal absorption, 
susceptibility to proteolysis, and instability in the bloodstream. 
We succeeded in designing minihepcidins of 7– or 9–amino acids 
in length that were active in mice in vivo. Intraperitoneal injec-
tion of proteolysis-resistant retro-inverso minihepcidins caused 
hypoferremia similar to that caused by native hepcidin. In a proof-
of-principle experiment, chronic administration of minihepcidins 
significantly decreased iron loading in a mouse model of heredi-
tary hemochromatosis. Hepcidin-1 knockout mice, which received 
intraperitoneal injections of a retro-inverso minihepcidin daily for 
2 weeks, had significantly lower liver iron content that hepcidin-1 
knockout mice injected with solvent.
Importantly, minihepcidin conjugated to fatty or bile acids 
caused hypoferremia after oral administration by gavage also. 
Given the number and rich variety of peptides involved in biologi-
cal processes, relatively few have been FDA approved as therapeu-
tics, and their efficient delivery by the oral route is still an unmet 
goal. Development of oral hepcidin analogs would represent a 
major advance in peptide pharmacology.
The mainstay of treatment for patients with iron overload 
is phlebotomy if they are not anemic and iron chelation if they 
have anemia. Although these measures are effective at reducing 
excess iron, they are frequently not well tolerated by patients, and 
compliance with iron-depleting therapy is suboptimal. If hepci-
din therapy proves to be effective and relatively free of side effects, 
it could represent a major improvement over existing therapies, 
either alone or in combination with current approaches to allow 
modifications that would make the treatment less burdensome 
and better accepted by patients.
Methods
Site-directed mutagenesis. For cysteine scanning of the ferroportin region 
M312-L345, the human ferroportin-GFP C205S/C326S mutant (12) was 
used as a template for site-directed mutagenesis. For alanine scanning of 
the region F324-S343, WT human ferroportin-GFP was used as a template. 
Primers were selected using the QuikChange Primer Design (https://www.
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genomics.agilent.com/), and mutagenesis was performed using Quik-
Change II XL Mutagenesis Kit (Agilent Technologies). Mutant plasmids 
were sequenced to verify the presence of the mutations.
Transient transfection and microscopy. WT and mutant ferroportin-GFP 
plasmids were transiently transfected into HEK293T cells using either Lipo-
fectamine 2000 (Invitrogen) or Amaxa nucleofection (Lonza) (12). Cells 
were visualized with an epifluorescence microscope (Nikon Eclipse), and 
images were acquired with a SPOT camera and SPOT Advanced Imaging 
Software (Diagnostic Instruments). Confocal microscopy was performed 
at the UCLA CNSI Advanced Light Microscopy Facility, using a Leica 
TCS-SP MP Confocal and Multiphoton Inverted Microscope equipped 
with an argon laser (488 nm blue excitation, JDS Uniphase). The images 
were acquired using a ×63 oil-immersion objective lens and LCS Lite Soft-
ware (Leica Confocal Software, Leica Microsystems).
Cell-surface biotinylation. Cells were treated with a nonpermeable SH-reac-
tive, maleimide-PEG2-biotin (12) (0.5 mM final concentration) according 
to the manufacturer’s instructions (Pierce). Each ferroportin-GFP con-
struct was analyzed in at least 3 independent experiments.
125I-hepcidin internalization assay. The assay was performed as described 
previously (12, 38). Cells were treated with 125I-hepcidin for 1 hour at 37°C. 
The radioactivity of untransfected cells was subtracted as background 
for each point. The counts were then normalized to the ferroportin-GFP 
expression of each sample as determined by quantitation of Western blots 
using Image Lab Software (Bio-Rad).
Immunoprecipitation and Western blotting. Cell lysis, immunoprecipitation, 
and Western blotting were performed as previously described (12). Polyclonal 
ab290 anti-GFP antibody (Abcam) was used for immunoprecipitation, bio-
tinylated proteins were detected with streptavidin-HRPO (Pierce), and a 
monoclonal anti-GFP antibody (clones 7.1 and 13.1, Roche) was used to 
determine the amount of ferroportin-GFP that was immunoprecipitated.
Surface plasmon resonance. Surface plasmon resonance was performed on 
a BIAcore 3000 System (BiaCore AB) as previously described (39). Peptides 
were immobilized on a CM5 sensor chip by the amine-coupling protocol at a 
range of response units (1,100–6,000 response units). Analyte solutions were 
prepared at concentrations of 1–10 μg/ml in HBS-EP buffer (10 mM HEPES, 
pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P20). Analytes were 
introduced into the flow cells at 50 μl/min for 3 minutes at 37°C. Resonance 
signals were corrected for nonspecific binding by subtracting the signal of the 
control flow cell and analyzed using BIAevaluation 4.1 software (Biacore).
Peptide synthesis and purification. All peptides were synthesized using the 
standard solid-phase fmoc chemistry (16) and were purified using reverse-
phase HPLC. Minihepcidins were synthesized as carboxyamides (-CONH2), 
which created a charge-neutral end more similar to a peptide bond than the 
negatively charged –COOH. The list of minihepcidins with their sequences 
is shown in Supplemental Table 2, and the structures of unnatural amino 
acids are displayed in Supplemental Table 3.
Circular dichroism spectroscopy. Circular dichroism spectra (185–260 nm) of 
the hepcidin peptides were recorded on a JASCO 720 Spectropolarimeter 
(Easton) as previously described (16). Estimates of the secondary structure 
contributions were made using the SELCON algorithm (40) and spectral 
basis set SP43 in the Olis Global Works software suite (Olis).
Modeling of hepcidin-ferroportin interaction. The structure for hepcidin (NP_
066998, http://www.ncbi.nlm.nih.gov/protein/NP_066998) was modeled 
by the coordinate set for the lowest energy conformer from the Protein 
Data Bank (PDB 2KEF) (18). The structure for ferroportin (NP_055400.1, 
http://www.ncbi.nlm.nih.gov/protein/NP_055400.1) was approximated 
using the coordinate set provided by Nathan Subramaniam (19). The fer-
roportin region spanning residues 306–362 and the hepcidin structure 
were individually minimized in the HyperChem environment to obtain 
the lowest energy conformer.
Hepcidin was first docked into the ferroportin segment using the initial-
stage docking program ZDOCK (http://zdock.bu.edu/). The lowest energy 
conformer set was then used as starting ensemble for a more refined dock-
ing using RosettaDock (http://rosettadock.graylab.jhu.edu/), which gen-
erated a low-energy structure used as a final hypothetical model for the 
ferroportin-hepcidin complex.
In vitro bioassay for measuring the activity of hepcidin derivatives. ECR293-
Fpn (38), a cell line stably transfected with the mouse ferroportin-GFP 
construct under the control of the ponasterone-inducible promoter, was 
used for flow cytometry measurements of GFP fluorescence as previously 
described (16). For each peptide, the treatment with the full range of 
peptide concentrations was repeated independently 3 to 7 times.
In vivo bioassay for measuring activity of hepcidin derivatives. Animal studies 
were approved by the Animal Research Committee at UCLA. Six-week-old 
C57BL/6 mice were obtained from The Jackson Laboratory. Mice were 
placed on an iron-deficient diet (~4 ppm iron, Harlan Teklad) for 2 weeks 
to suppress endogenous hepcidin and to decrease its mouse-to-mouse 
variability (16, 41). Mice were subjected to the following treatments: (a) 
intraperitoneal injection with 0, 20, or 200 nmoles peptide solubilized 
in 100 μl SL220 solubilization agent (NOF) and (b) gavage with 0 or 200 
nmoles peptide in 250 μl 1× solvent (Cremophor EL [Sigma-Aldrich]/etha-
nol/PBS = 12.5:12.5:75) (42). Mice were sacrificed 4 hours later, and serum 
iron was determined using a colorimetric assay (Diagnostic Chemicals) 
(16). To normalize for the variations in absolute serum iron levels among 
experiments, the results were expressed as the percentage of decrease in 
serum iron as compared with the serum iron levels in PBS-treated mice. 
Each peptide concentration was tested in 5 to 7 animals.
For the study of chronic minihepcidin effects, we used hepcidin-1 knock-
out mice, originally provided to our laboratory by Sophie Vaulont (43). 
Hamp1–/– mice (5–6 weeks of age, 6 males, and 7 females) were placed on 
low-iron diet for 2 weeks (4 ppm iron) to slow down the development of 
iron overload prior to injections with minihepcidins. The mice were then 
switched to the standard mouse chow (336 ppm iron) and given 100 μl 
intraperitoneal injections daily of either 100 nmoles palmitoyl-ri-hep9 
solubilized in SL220 or the solvent only. After 2 weeks, the mice were 
euthanized, and their nonheme liver iron concentration was measured. 
Nonheme iron concentration was determined as described (44), using 
acid-based protein precipitation followed by a colorimetric assay for iron 
quantitation (Diagnostic Chemicals).
Quantitative real-time PCR. Liver RNA was extracted using TRIzol reagent 
(Invitrogen). Gene expression of Hamp1 and the reference gene β-actin 
(Actb) was assessed by qRT-PCR using the iScript cDNA Synthesis Kit and 
iQ SYBR Green Supermix (Bio-Rad) (45). HAMP1 primer sequences are 
as follows: 5′-TTGCGATACCAATGCAGAAGA-3′ and 5′-GATGTGGCTC-
TAGGCTATGTT-3′. β-Actin primer sequences are as follows: 5′-ACCCA-
CACTGTGCCCATCTA-3′ and 5′-CACGCTCGGTCAGGATCTTC-3′.
Statistics. SigmaPlot version 11.0 (Systat Software) was used for statistical 
analyses. A P value of less of 0.05 was considered significant.
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